AT Concentrates Market to Value USD 120 Million by 2019, Says GBI Research
17 Jun 2013 • by Natalie Aster
Clinical studies are desperately required to prove the safety, efficacy and cost-effectiveness of blood proteins used in critical care. Alongside individuals with rare hematological conditions, patients undergoing surgery can benefit from blood protein treatment. However, prothrombin complex concentrates (PCCs), albumin, antithrombin (AT) concentrates, and factor concentrates remain controversial treatments due to a lack of clinical data and consensus among specialists.
The antithrombin (AT) concentrates market is competitive, containing at least eight different AT III products, including Talecris' anti-thrombin product, Thrombate, and rEVO Biologics' Atryn (recombinant AT). Atryn is genetically bioengineered, removing dependence on plasma donors, minimizing risk of viral transmission, and allowing speedier production.
The cost of therapy with AT concentrates is high compared to other anticoagulant and plasma products, but its impressive safety and efficacy outweigh this concern. The AT concentrates market is expected to increase at a CAGR of 6.1%, from an estimated $79m in 2012 to $120m by 2019.
In-demand report "Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific" by GBI Research analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US and the top five countries of Europe (the UK, Germany, France, Italy and Spain). The report also provides an overview on Asia-Pacific countries, including Japan, China, India and Australia.
Major marketed products in the critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets are also included. The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market.
Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific
Published: May, 2013
Price: US$ 3,500.00
More information can be found in the report “Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific” by GBI Research.
To order the report or ask for sample pages contact [email protected]